RecruitingOBSERVATIONAL

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

This research study focuses on a rare and aggressive type of blood cancer called transformed splenic marginal zone lymphoma (t-SMZL). Currently, there aren't specific treatments for t-SMZL, and understanding of its causes is limited, often leading to poor outcomes for patients. Researchers aim to collect and study existing medical information and tissue samples from patients with t-SMZL. By looking closely at the details of this condition, including its genetic make-up, they hope to gain a much clearer picture of how it develops and progresses. The goal is to use this new knowledge to help doctors make better decisions about treatment and ultimately develop new, more effective therapies tailored specifically for people living with t-SMZL.

At a glance

Status

Recruiting

Sponsor

International Extranodal Lymphoma Study Group (IELSG)

Enrolment target

100

Start

13 Oct 2025

Estimated completion

01 Mar 2029

Transformed Splenic Marginal Zone Lymphoma

What is this study about?

This study is about a rare type of blood cancer called transformed splenic marginal zone lymphoma, or t-SMZL. When diagnosed, this condition can be quite serious, and currently, there aren't any specific treatments designed just for it. This means doctors have to use treatments meant for other similar conditions, which aren't always as effective. Because of this, it's really important to learn more about t-SMZL so we can find better ways to help patients.

The main aim of this research is to understand t-SMZL much better. Researchers will do this by looking back at information already collected from patients. This includes their medical records and stored tissue samples, like those taken from the spleen or bone marrow. By examining these details, like how the disease changed over time and its genetic information, scientists hope to piece together a clearer picture of what makes t-SMZL behave the way it does.

Ultimately, the knowledge gained from this study is crucial for the future. By understanding the disease's complexities, researchers hope to develop new and more specific treatments. Finding these targeted treatments could significantly improve the outlook for people with t-SMZL, offering them more effective and tailored care.

Key takeaways

Studies a rare form of blood cancer called t-SMZL.
Uses existing patient medical records and tissue samples.
Aims to understand the disease better for future treatments.
No new tests or treatments for participants.
Information gathered will only help future patients.

Who may be eligible?

To be part of this study, you need to be an adult, aged 18 or older. No matter your gender, you are welcome to be considered.

You must have a diagnosis of transformed splenic marginal zone lymphoma (t-SMZL). This could be diagnosed at the same time as your original splenic marginal zone lymphoma, or it could have happened later on.

Crucially, there must be existing tissue samples from your diagnosis of t-SMZL available for the researchers to study. These samples might come from different parts of your body, like your spleen or bone marrow. The study will also look for earlier samples if you had your original splenic marginal zone lymphoma diagnosed before the transformation.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been diagnosed with transformed splenic marginal zone lymphoma (t-SMZL)?
Are past tissue samples from your t-SMZL diagnosis available?
Is your medical history related to your cancer available for review?

Answer every question to see your result.

What does participation involve?

Taking part in this study won't involve any new hospital visits, tests, or treatments for you. This is because the researchers are only looking at information that's already been collected. They will be reviewing your past medical records and any tissue samples that were taken as part of your normal care. You won't be asked to take any new medication or go through any extra procedures. Your participation simply means allowing the researchers to learn from your existing medical data to help others in the future.

Potential risks and benefits

There are no direct risks to you for taking part in this study because you will not undergo any new tests, procedures, or treatments. Your personal information will be kept confidential and anonymised for research. While this study won't directly benefit you as an individual patient, the information learned will be incredibly valuable in helping doctors and scientists understand transformed splenic marginal zone lymphoma better and develop more effective treatments for future patients. You are free to withdraw your consent for your data to be used at any time without it affecting your medical care.

Locations (7)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Columbia University
Verified postcode
New York, United States· Not yet recruiting
Universitz Hospitals Leuven
Verified postcode
Leuven, Belgium· Not yet recruiting
Hôpital Saint Louis
Verified postcode
Paris, France· Recruiting
Fondazione IRCCS Policlinico San Matteo
Verified postcode
Pavia, Italy· Recruiting
Hospital Clínic de Barcelona
Verified postcode
Barcelona, Spain· Recruiting
Oncology Institute of Southern Switzerland
Verified postcode
Bellinzona, Switzerland· Not yet recruiting
University Hospitals Dorset
Verified postcode
Bournemouth, United Kingdom· Not yet recruiting

Common questions

What is 'transformed splenic marginal zone lymphoma'?

It's a rare and more aggressive type of blood cancer that can develop from splenic marginal zone lymphoma.

Will I have to do anything new for this study?

No, this study only uses existing medical information and tissue samples already collected from your past care. You won't have any extra visits or tests.

Will this study help me directly?

No, this study won't directly change your treatment or care. However, the information learned will help future patients with this condition.

How will my personal information be kept private?

Your identity will be kept separate from your medical information and samples, ensuring your privacy is protected.

What is the main goal of this research?

The main goal is to understand this rare cancer better so that more specific and effective treatments can be developed in the future.

How to find out more

IELSG Study Coordination Office

ielsg@ior.usi.ch +41 58 666 7321 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.